Foundation Medicine is launching FoundationOne PGx in the U.S. through an expanded partnership with Fulgent Genetics, aiming to help oncology clinicians predict toxicity, reduced efficacy and adverse reactions before or during treatment. The pharmacogenetic panel includes DPYD and other oncology-relevant genes tied to metabolism of commonly used chemotherapies, targeted therapies and supportive care medicines.

Why It Matters To Oncology

• FoundationOne PGx is designed to identify inherited genetic differences that affect how patients metabolize cancer drugs and supportive medicines.

• Foundation said the test focuses on genes with strong clinical evidence and actionable guidance, which could support dosing and regimen decisions.

• The assay may be useful early in a patient’s disease course or later in advanced disease, when combination regimens can complicate toxicity management.

The Financials

• The launch expands Foundation Medicine’s commercial partnership with Fulgent Genetics after the companies paired up last year in hereditary cancer testing.

• In February 2025, the companies said they would launch FoundationOne Germline and FoundationOne Germline More in the U.S.

• The PGx rollout also follows Foundation’s agreement to acquire SAGA Diagnostics for up to $595 million, broadening its cancer monitoring business with MRD capabilities.

What They're Saying

• Chief Medical Officer Todd Druley said FoundationOne PGx is meant to help providers anticipate potential toxicity, reduced treatment effectiveness and increased risk of adverse reactions.

• Foundation positioned the test as an addition to its oncology portfolio that can be ordered through its existing portal.

What's Next

• Clinicians will be watching how quickly Foundation integrates PGx testing into routine oncology workflows alongside comprehensive genomic profiling and germline offerings.

• Key questions include payer uptake, ordering patterns and whether the test meaningfully changes chemotherapy, targeted therapy or supportive care prescribing.

• Drug developers may also track whether broader PGx adoption sharpens patient selection and toxicity management in oncology practice.